MedTrace Logo

A Prospective Study of EUS Guided Celiac Block

NCT00583271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2014-09-05

No results posted yet for this study

Summary

The purpose of this prospective study is to measure the clinical effectiveness of EUS-guided CB in subjects, 50 who have chronic pancreatitis and 50 who have pancreatic cancer, that are already undergoing celiac block for clinical reasons.

Conditions

Interventions

DRUG

triamcinolone

80mg of triamcinolone injected into the celiac ganglion during the EUS-CB

DRUG

98% dehydrated alcohol

10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Julia LeBlanc, MD, MPH · Indiana University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00583271 on ClinicalTrials.gov